Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension

Heart

Volumn 80, Issue 2, 1998, Pages 151-155

  Higenbottam, T ^a   Butt, A Y ^b   McMahon, A ^b   Westerbeck, R ^b,c   Sharples, L ^b,c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b PAPWORTH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Event free survival; Iloprost; Prostacyclin; Pulmonary hypertension

Indexed keywords

ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; ILOPROST; PROSTACYCLIN;

ADULT; ARTICLE; CONTROLLED STUDY; ENDARTERECTOMY; FEMALE; HEART RIGHT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; TREATMENT OUTCOME; VASODILATATION;

EID: 0031842301     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.80.2.151     Document Type: Article

References (19)

1. Abenheim I, Mondes Y, Brenot F, et al Appetite-suppressant drugs and risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-16.
2. Barst R, Rubin L, Long W, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
3. Higenbottam TW Prostacyclin. Bandolier 1995;14:3-4.
4. Jones DK, Higenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin). Br Heart J 1987;57:270-8.
5. Stein PD, Hull RD, Saltzman HA, et al. Strategy for diagnosis of patients with suspected pulmonary emboli. Chest 1993;103:1553-9.
6. McGavin CR, Gupta SP, McHardy GJR. Twelve minute walking test for assessing disability in chronic bronchitis. BMJ 1976;i:822-3.
7. Higenbottam TW, Wheeldon D, Wells F, et al. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;i:1046-7.
8. De La Mata J, Gomez-Sanchez MA, Aranzana M, et al. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 1994;37:1528-33.
9. Butt AY, Dinh-Xaun T, Takao M, et al. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue iloprost. Heart 1998;79:175-9.
10. Rich S, Kaufman E, Levy P. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
11. Dawkins KD, Jamieson SW, Hunt SA, et al. Long-term results, hemodynamics, and complications after combined heart and lung transplantation. Circulation 1985;71:919-26.
12. Moser KM, Fedullo PF, Auger WR, et al. Chronic thromboembolic pulmonary hypertension: clinical picture and surgical treatment. Eur Resp J 1992;5:334-43.
13. D'Alonzo GE, Barst RJ, Ayres SM. Survival in patients with primary pulmonary hypertension. Ann Intern Med 1991; 115:343-9.
14. Fuster V, Steele PM, Edwards WD. Primary pulmonary hypertension: natural history and importance of thrombosis. Circulation 1984;70:580-7.
15. Higenbottam TW, Spiegelhalter D, Scott J, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments of severe pulmonary hypertension. Br Heart J 1993;70:366-70.
16. Hopkins WE, Ochoa LL, Richardson GW, et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger's syndrome. J Heart Lung Transplant 1996;15:100-5.
17. Brown G. Pharmacological treatment of primary and secondary pulmonary hypertension. Pharmacology 1991; 11:137-56.
18. Hosenpud JD, Novick RJ, Bennett LE, et al. The registry of the International Society for Heart and Lung Transplantation: thirteenth official report - 1996. J Heart Lung Transplant 1996;15:655-74.
19. Higenbottam TW, Ward SE, Brennan A, et al. Prostacyclin in the treatment of primary pulmonary hypertension. Sheffield: Trent Institute for Health Services Research, Universities of Leicester, Nottingham and Sheffield, 1997. (Guidance note for purchasers: 97/02.)